CYBB and familial dilated cardiomyopathy: Our study proved the positive effect of Dapa on DCM treatment by inhibiting the expressions of mechanical signaling proteins (i.e., angiotensin II type 1 receptor (AT1R)), which reduces the downstream expressions of focal adhesion kinase (FAK) and NADPH oxidase 2 (NOX2) and leads to the decreased production of reactive oxygen species (ROS) (Scheme 1B), and Dapa had a more significant therapeutic effect on DCM than those under stiffer ECM conditions.